The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
about
Current status of hematopoietic stem cell transplant in chronic myeloid leukemiaImpact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia.Targeted treatment of chronic myeloid leukemia: role of imatinib.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrImpact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaChronic myelogenous leukemia: role of stem cell transplant in the imatinib era.The role of stem cell transplantation for chronic myelogenous leukemia in the 21st centuryJanus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisPretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcomeAllogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin.BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts.Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors.Role of allo-SCT for CML in 2010.Stem cell transplant for chronic myeloid leukemia in the imatinib eraRole of allogeneic transplantation in chronic myeloid leukemia.Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Treatment options for chronic myeloid leukemia.Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.Allogeneic transplant for chronic myeloid leukemia in 2010.Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China.HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase.Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
P2860
Q27010475-AC60FEA4-9D6B-4724-8A3A-6E4DB30CEB34Q33886172-CFFFA1DA-273F-4ECE-9181-610B402CA336Q33915973-7EDE5A7F-C812-4771-90E6-638873F6944BQ34044024-64F8F881-81F6-454E-BD7D-4EC9EC839683Q34198055-E1E90B36-1F69-4142-BC02-E90F04D15132Q34522789-38BA076E-EB39-467C-9BF9-6A5420C796E3Q35633858-EAB8CCF8-E917-446A-8D88-FAE30FFF8EC7Q35634865-007A8F44-1F08-472C-A8F8-50D8594173E4Q35735663-7E8FBE55-B88A-4651-A738-755B7EE419A7Q36059184-2BAE2A81-9CE1-44D6-AF80-D1222B394585Q36741655-C3C4DA4B-CB02-4ABB-B0CE-C0765C619908Q36822880-A26A3A41-DF4B-4258-8D07-F665A3927AF2Q37051056-760A8E0A-F343-49E2-9514-DBCE88E42436Q37132850-A9E70610-F8CF-4930-B792-0BCA802741E1Q37163550-B3B43098-11EA-441E-BDC8-5D605B66128BQ37360559-F65CF563-B214-4554-82FA-508B53EDB68EQ37428676-1A738FD7-DEBE-4F2B-BADA-B6D08CDD4777Q37497977-E541BAB4-88A7-48FC-B204-387D605D60C0Q37505017-C455C972-C846-4D83-8454-C2F908B5D7E5Q37657492-8C69FE98-BB91-4FDF-A97D-2374E3E9AB62Q37763493-1E13D8DA-B11D-44F4-8F7A-F63DAB6BF2EFQ37793491-202285F0-BA5F-43A3-AEF1-DB7CC06523DEQ37810113-D4CBF10D-8B9F-43E0-B734-C30F03563977Q37853793-309FBBAF-F7AC-4255-B228-16CD90E0C001Q37994805-46D4EFA2-505C-49E4-B22A-20C7658BF2D7Q38204330-CC5013FD-CC19-4F82-B984-B3561C9DE845Q38585916-D87B9930-4B54-4155-8C03-C45B285AF289Q38757051-86CB99BB-F19D-4FAE-B2D1-0AAC438BB98AQ38764223-F869585B-1473-4B3C-9D67-E7CA7270D2F0Q40957470-84900C74-B8B7-4F76-920E-D05905A10E15Q41874881-E13EC0E6-31D6-4F17-9A2B-E10EE69B6BB2Q42203455-44A0E674-7B04-46DC-96FA-5E39E048A096Q43168908-9409E1AE-4E48-4053-BE39-8238F047F739Q45129016-74B22DD3-3B7C-4525-BE0A-B723599267B8Q46127678-63ED8ED0-7565-45B4-A1A6-40B62D4A12E5Q46413329-3D330B3E-A136-411A-A35F-DDA6A1BB79E0Q46446514-2FB05C13-A5B2-4FE1-AAEF-F7CB1A829490Q46737739-CCB15D60-94B6-46BC-B008-2AF24F283166Q53004947-13FE8B9B-F0A2-46D3-9ACF-887C805DB35CQ54546815-7419A242-3DE1-43EA-AEBD-285F8A97D0BA
P2860
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The effects of imatinib mesyla ...... n for chronic myeloid leukemia
@ast
The effects of imatinib mesyla ...... n for chronic myeloid leukemia
@en
type
label
The effects of imatinib mesyla ...... n for chronic myeloid leukemia
@ast
The effects of imatinib mesyla ...... n for chronic myeloid leukemia
@en
prefLabel
The effects of imatinib mesyla ...... n for chronic myeloid leukemia
@ast
The effects of imatinib mesyla ...... n for chronic myeloid leukemia
@en
P2093
P2860
P1433
P1476
The effects of imatinib mesyla ...... n for chronic myeloid leukemia
@en
P2093
Carrie C Cummings
David S Snyder
Jerald P Radich
Laura Johnston
Ravi Bhatia
Robert S Negrin
Stephen J Forman
Ted Gooley
P2860
P304
P356
10.1182/BLOOD-2006-06-031682
P407
P577
2006-10-24T00:00:00Z